8. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) ranks eighth as one of the most prominent publicly traded AI drug-discovery companies. Shares traded near $3.63, placing the stock within reach of investors searching for cheap AI stocks under $5. Its approximately $1.9 billion market capitalization, however, shows why share price cannot be used as the only measure of value.
The company combines automated laboratory experiments, biological imaging, machine learning and large-scale computing to search for relationships between diseases, genes and potential treatments. Instead of asking researchers to examine one hypothesis at a time, its platform is designed to run and analyze vast numbers of experiments in parallel.
The combination with Exscientia expanded its computational chemistry capabilities and development pipeline. The larger organization now controls more scientific data, additional drug candidates and a broader set of pharmaceutical partnerships. Its collaborations could produce milestone payments if programs advance successfully.
One encouraging development came when a major biotechnology partner selected the first neuroscience target from their research collaboration for advancement into early discovery. That decision offered some external validation of the platform, although an early discovery target remains many steps away from becoming an approved medicine.
Cash, cash equivalents and restricted cash totaled $556.8 million at the end of June 2026. Management expects the existing capital to support operations into early 2028 without additional financing. The company reported the cash runway and latest partnership progress in its second-quarter update.
The concern is cash consumption. The company began 2026 with approximately $753.9 million, meaning a significant amount of capital was used during the first half. Clinical trials and platform development remain expensive, and additional financing could eventually become necessary.
This remains one of the most interesting AI biotech stocks for aggressive investors. If its operating system repeatedly produces successful drug candidates, the current valuation could eventually look modest. If clinical programs disappoint, however, even an impressive technology platform may not protect shareholders.
